SCHEMBL1285877

SCHEMBL1285877

Cc1nc2cc(N)cc(C)c2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.38
▸ KDM4E B2RXH2 6/20 0.38
▸ MAPT P10636 6/20 0.38
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ POLB P06746 3/20 0.38
▸ GAA P10253 3/20 0.38
▸ GFER P55789 2/20 0.38
▸ GLA P06280 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ FABP6 P51161 1/20 0.37
▸ HPGD P15428 4/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ RPS6KA3 P51812 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ RECQL P46063 1/20 0.34
▸ PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1285633 0.98 ALDH1A1 (0.37) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL6621861 0.84 FABP6 (0.50) ALDH1A1KDM4EMAPTGAAMEN1
SCHEMBL7031600 0.81 KDM4E (0.36) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL13351381 0.81 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL5850166 0.79 PARP1 (0.43) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL13868960 0.78 FABP6 (0.33) ALDH1A1KDM4EMAPTNPC1POLB
SCHEMBL2922182 0.77 TYMS (0.35) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL12501311 0.77 MAPT (0.41) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL13350479 0.77 MAPT (0.47) ALDH1A1KDM4EMAPTPOLBGAA
SCHEMBL16789843 0.77 TDP1 (0.38) ALDH1A1KDM4EMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 — — EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 — — EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 — — WO disclosed
WO-2009034029-A2 1-SUBSTITUTED 4-HETEROCYCLYLPIPERIDINES FOR USE AS CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 ALDH1A1 887/4885KDM4E 4588/4885MAPT 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback